

10/21/2005 10685722.trn

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1	Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	"Ask CAS" for self-help around the clock
NEWS 3 JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS 4 AUG 11	STN AnaVist workshops to be held in North America
NEWS 5 AUG 30	CA/CAPLUS - Increased access to 19th century research documents
NEWS 6 AUG 30	CASREACT - Enhanced with displayable reaction conditions
NEWS 7 SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 8 OCT 03	MATHDI removed from STN
NEWS 9 OCT 04	CA/CAPLUS-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS 10 OCT 06	STN AnaVist workshops to be held in North America
NEWS 11 OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS 12 OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAPLUS documents for use in third-party analysis and visualization tools
NEWS EXPRESS	JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:44:18 ON 21 OCT 2005

=>

Uploading

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

10/21/2005 10685722.trn

Do you want to switch to the Registry File?

Choice (Y/n):

Switching to the Registry File...

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:44:29 ON 21 OCT 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 OCT 2005 HIGHEST RN 865652-03-5  
DICTIONARY FILE UPDATES: 19 OCT 2005 HIGHEST RN 865652-03-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*


Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10685722.str



chain nodes :

28 29 30 31 32 34

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23  
24 25 26 27

chain bonds :

4-30 8-32 11-28 17-26 20-34 25-28 27-29 30-31 31-32

ring bonds :

1-2 1-5 2-3 3-4 4-5 6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-23 13-14  
14-15 15-24 16-17 16-21 17-18 18-19 19-20 20-21 22-23 22-27 23-24 24-25  
25-26 26-27

exact/norm bonds :

3-4 4-5 4-30 8-32 27-29 31-32

exact bonds :

1-2 1-5 2-3 11-28 17-26 20-34 22-23 22-27 24-25 25-26 25-28 26-27 30-31

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-23 13-14 14-15 15-24 16-17 16-21  
17-18 18-19 19-20 20-21 23-24

isolated ring systems :

containing 1 : 6 : 12 : 16 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom  
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:CLASS  
29:CLASS 30:CLASS 31:CLASS 32:CLASS 34:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

10685722.trn

Structure attributes must be viewed using STN Express query preparation.

=> s 11

SAMPLE SEARCH INITIATED 12:44:45 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED  
SEARCH TIME: 00.00.01

## 5 ITERATIONS

### 3 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS:            5 TO        234

PROJECTED ANSWERS: 3 TO 163

L2                      3 SEA SSS SAM L1

=> s ll sss full

FULL SEARCH INITIATED 12:44:51 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 93 TO ITERATE

100.0% PROCESSED      93 ITERATIONS


SEARCH TIME: 00.00.01

27 ANSWERS

L3 27 SEA SSS FUL L1

$$= \gamma$$

Uploading C:\Program Files\Stnexp\Queries\10685722a.str



chain nodes :

28    29    30    31    32    34    36

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23  
24 25 26 27

chain bonds :

4-30    8-32    11-28    13-36    17-26    20-34    25-28    27-29    30-31    31-32

ring bonds :

1-2   1-5   2-3   3-4   4-5   6-7   6-11   7-8   8-9   9-10   10-11   12-13   12-23   13-14

14-15 15-24 16-17 16-21 17-18 18-19 19-20 20-21 22-23 22-27 23-24 24-25

25-26      26-27

10/21/2005 10685722.trn

exact/norm bonds :

3-4 4-5 4-30 8-32 13-36 27-29 31-32

exact bonds :

1-2 1-5 2-3 11-28 17-26 20-34 22-23 22-27 24-25 25-26 25-28 26-27 30-31

normalized bonds :

6-7 6-11 7-8 8-9 9-10 10-11 12-13 12-23 13-14 14-15 15-24 16-17 16-21  
17-18 18-19 19-20 20-21 23-24

isolated ring systems :

containing 1 : 6 : 12 : 16 :

G1:X,Ak,CH3,CF3

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom  
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:CLASS  
29:CLASS 30:CLASS 31:CLASS 32:CLASS 34:CLASS 36:CLASS

L4 STRUCTURE UPLOADED

=> d l4

L4 HAS NO ANSWERS

L4 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l4

SAMPLE SEARCH INITIATED 12:46:41 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 5 TO 234

PROJECTED ANSWERS: 1 TO 80

L5 1 SEA SSS SAM L4

=> s l4 sss ~~full~~

FULL SEARCH INITIATED 12:46:47 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 93 TO ITERATE

100.0% PROCESSED 93 ITERATIONS

SEARCH TIME: 00.00.01

7 ANSWERS

L6 7. SEA SSS FUL L4

=> d his

10/21/2005 10685722.trn

(FILE 'HOME' ENTERED AT 12:44:18 ON 21 OCT 2005)

FILE 'REGISTRY' ENTERED AT 12:44:29 ON 21 OCT 2005

L1 STRUCTURE UPLOADED  
L2 3 S L1  
L3 27 S L1 SSS FULL  
L4 STRUCTURE UPLOADED  
L5 1 S L4  
L6 7 S L4 SSS FULL

=> FIL HCAPLUS

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
323.52	323.73

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 12:46:56 ON 21 OCT 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Oct 2005 VOL 143 ISS 18

FILE LAST UPDATED: 20 Oct 2005 (20051020/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13

L7

5 L3

=> s 16

L8

2 L6

=> d 17 ibib abs hitstr tot

L7 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:283488 HCAPLUS

DOCUMENT NUMBER: 142:336252

TITLE: Preparation of benzopyranone derivatives as inhibitors of the release of IL-6 production

INVENTOR(S): Mckie, Jeffrey A.; Bhagwat, Shripad S.; Renaud, Johannes; Missbach, Martin

PATENT ASSIGNEE(S): Signal Pharmaceuticals, Llc, USA; Novartis Ag

SOURCE: PCT Int. Appl., 76 pp.



CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005028472	A1	<del>20050331</del>	WO 2004-US30141	20040913
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005137231	A1	20050623	US 2004-942519	20040915
PRIORITY APPLN. INFO.:			US 2003-503295P	P 20030915
OTHER SOURCE(S):			MARPAT 142:336252	
GI				



AB Title compds. represented by the formula I. [wherein X, Y = independently H, halo or (halo)alkyl; n = 1-3; R1 = H or Me; R2 = halo, OH, vinyl, CO2H, etc.; and pharmaceutically acceptable salts thereof] were prepared as inhibitors of the release of IL-6 production. For example, II was given in a multi-step synthesis starting from the reaction of 3-methoxyphenol with 4-hydroxyphenylacetic acid. I showed inhibition of the release of IL-6 production, MCF-7 breast cancer cell proliferation, and the growth of BG-1 ovarian cancer cells. Thus, I and their pharmaceutical compns. are useful for the treatment or prevention of a bone-resorbing disease, a neoplastic disease, arthritis, and etc.

IT **848749-18-8P**, 3-(2,4-Dichlorophenyl)-7-hydroxy-6-methyl-4-[4-[2-(pyrrolidin-1-yl)ethoxy]benzyl]chromen-2-one **848749-19-9P**,

10/21/2005

10685722.trn


3-(2,4-Dichlorophenyl)-7-hydroxy-8-methyl-4-[4-[2-(pyrrolidin-1-yl)ethoxy]benzyl]chromen-2-one **848749-24-6P**,  
8-Acetyl-3-(2,4-dichlorophenyl)-7-hydroxy-4-[4-[2-(pyrrolidin-1-yl)ethoxy]benzyl]chromen-2-one

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzopyranone derivs. as inhibitors of the release of IL-6 production)


RN 848749-18-8 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-(2,4-dichlorophenyl)-7-hydroxy-6-methyl-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 848749-19-9 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-(2,4-dichlorophenyl)-7-hydroxy-8-methyl-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 848749-24-6 HCAPLUS

CN 2H-1-Benzopyran-2-one, 8-acetyl-3-(2,4-dichlorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




IT 848749-23-5P, 3-(2,4-Dichlorophenyl)-7-hydroxy-8-iodo-4-[4-[2-(pyrrolidin-1-yl)ethoxy]benzyl]chromen-2-one

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzopyranone derivs. as inhibitors of the release of IL-6)

production)  
 RN 848749-23-5 HCAPLUS  
 CN 2H-1-Benzopyran-2-one, 3-(2,4-dichlorophenyl)-7-hydroxy-8-iodo-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:392330 HCAPLUS

DOCUMENT NUMBER: 140:391197

TITLE: Preparation of benzopyranone compounds for modulating estrogen receptor expression

INVENTOR(S): Renaud, Johanne; Missbach, Martin; McKie, Jeffrey A.; Bhagwat, Shripad S.

PATENT ASSIGNEE(S): Switz.

SOURCE: U.S. Pat. Appl. Publ., 26 pp., Cont.-in-part of U.S. Ser. No. 125,965.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004092572	A1	20040513	US 2003-412997	20030414
US 6620838	B1	20030916	US 2002-125965	20020419
CA 2482986	AA	20031030	CA 2003-2482986	20030418
WO 2003089422	A1	20031030	WO 2003-US12283	20030418

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,

PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,  
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1497277 A1 20050119 EP 2003-733871 20030418

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:



US 2002-125965 A2 20020419

US 2003-412997 A 20030414

WO 2003-US12283 W 20030418

OTHER SOURCE(S): MARPAT 140:391197

GI



AB Benzopyranone compds. of formula I [R = H, acyl, etc.; X = H, halo, CF<sub>3</sub>; Y = halo, CF<sub>3</sub>; n = 2-4] are prepared for modulating gene expression in a cell expressing estrogen receptor (ER). The compds. of formula I wherein R is H can be prepared by demethylation of the corresponding phenolic Me ether. The compds. are useful for treating a bone-resorbing disease, cancer, arthritis or an estrogen-related condition such as breast cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, and adverse reproductive effects associated with exposure to environmental chems. or natural hormonal imbalances. Thus, II was prepared from (2-chloro-4-trifluoromethylphenyl)acetic acid, 1-(2-hydroxy-4-methoxyphenyl)-2-(4-hydroxyphenyl)ethan-1-one and 1-(2-chloroethyl)pyrrolidine hydrochloride. The IC<sub>50</sub> of II against MCF-7 breast cancer cell was 4.5 nM.

IT 601513-02-4P 601513-06-8P 601513-07-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of benzopyranone compds. for modulating estrogen receptor expression)


RN 601513-02-4 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-[4-chloro-2-(trifluoromethyl)phenyl]-7-hydroxy-4-  
[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 601513-06-8 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-(2,4-dichlorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-07-9 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-(4-chlorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



IT 601513-35-3P 601513-44-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzopyranone compds. for modulating estrogen receptor expression)

10/21/2005 10685722.trn


RN 601513-35-3 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-[4-chloro-2-(trifluoromethyl)phenyl]-7-methoxy-4-  
[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-44-4 HCAPLUS


CN 2H-1-Benzopyran-2-one, 3-(2,4-dichlorophenyl)-7-methoxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



10/21/2005 10685722.trn

L7 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2004:354751 HCAPLUS  
DOCUMENT NUMBER: 140:350547  
TITLE: Benzopyranone compounds, compositions thereof, and  
methods for treating or preventing cancer  
INVENTOR(S): Friedman, Glenn; McKie, Jeffrey; Wright, Jonathan  
PATENT ASSIGNEE(S): Signal Pharmaceuticals, Llc, USA  
SOURCE: PCT Int. Appl., 34 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004035002	A2	20040429	WO 2003-US32932	20031015
WO 2004035002	A3	20040826		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004225005	A1	20041111	US 2003-685722	20031014
CA 2502064	AA	20040429	CA 2003-2502064	20031015
EP 1556374	A2	20050727	EP 2003-777639	20031015
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003015400	A	20050816	BR 2003-15400	20031015
PRIORITY APPLN. INFO.:			US 2002-418469P	P 20021015
			US 2003-685722	A 20031014
			WO 2003-US32932	W 20031015
OTHER SOURCE(S):	MARPAT 140:350547			
GI				



AB This invention relates to benzopyranone compds., compns. comprising a benzopyranone compound and methods for treating or preventing cancer or inhibiting the growth of a cancer cell or neoplastic cell comprising administering an effective amount of a benzopyranone compound. The benzopyranone compds. have the formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is halogen, trifluoromethyl or C1-6 alkyl. A

solution of the phenolbenzopyranone (0.74 mmol), triphenylphosphine (1.1 mmol), and 1-(2-hydroxyethyl)pyrrolidine (1.1 mmol) in THF/CH<sub>2</sub>Cl<sub>2</sub> (8 mL) was treated with DIAD (1.1 mmol) and the reaction mixture was stirred at room temperature for about 6 h. The reaction mixture was concentrated and the crude

product was purified using flash chromatog. to provide about 35 mg (10%) of 13-(4-chlorophenyl)-7-fluoro-4-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-chromen-2-one.


IT 681813-32-1P 681813-35-4DP, derivs.

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(benzopyranone compds., compns. thereof, and methods for treating or preventing cancer)


RN 681813-32-1 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-(4-chlorophenyl)-7-fluoro-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 681813-35-4 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-(4-chlorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L7 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:855919 HCAPLUS

DOCUMENT NUMBER: 139:350634

TITLE: Preparation of benzopyranone compounds as inhibitors of interleukin-6 release, antitumor agents, etc.

INVENTOR(S): McKie, Jeffrey A.; Bhagwat, Shripad S.; Renaud, Johanne; Missbach, Martin

PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA; Novartis A.-G.

SOURCE: PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003089422	A1	20031030	WO 2003-US12283	20030418
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW:				
GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 6620838	B1	20030916	US 2002-125965	20020419
US 2004092572	A1	20040513	US 2003-412997	20030414
CA 2482986	AA	20031030	CA 2003-2482986	20030418
EP 1497277	A1	20050119	EP 2003-733871	20030418
R:				
AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

10/21/2005 10685722.trn

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
PRIORITY APPLN. INFO.: US 2002-125965 A 20020419  
US 2003-412997 A 20030414  
WO 2003-US12283 W 20030418  
OTHER SOURCE(S): MARPAT 139:350634  
GI



AB The title compds. I [A = (CH<sub>2</sub>)<sub>n</sub>; n = 2 to 4; R<sub>1</sub> = H, COR<sub>2</sub>, etc.; R<sub>2</sub> = alkyl, etc.; X = H, halo, etc.; Y = halo, etc.] are prepared I are useful for treating a bone-resorbing disease, cancer, arthritis or an estrogen-related condition such as breast cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, and adverse reproductive effects associated with exposure to environmental chems. or natural hormonal imbalances. Compds. of this invention inhibit both MCF-7 breast cancer and BG-1 ovarian carcinoma cell proliferation; they showed IC<sub>50</sub> values of 1.4 nM to 13.6 nM against BG-1 ovarian carcinoma cells and IC<sub>50</sub> values of 3 nM to 13.6 nM against MCF-7 breast cancer cells.


IT 601513-02-4P 601513-06-8P 601513-07-9P  
601513-17-1P 601513-18-2P 601513-19-3P  
601513-35-3P 601513-44-4P 618885-77-1P  
618885-78-2P 618885-79-3P 618885-80-6P  
618885-81-7P 618885-82-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzopyranone compds. as inhibitors of interleukin 6 release, and antitumor agents)


RN 601513-02-4 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-[4-chloro-2-(trifluoromethyl)phenyl]-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 601513-06-8 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-(2,4-dichlorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 601513-07-9 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-(4-chlorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 601513-17-1 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-(4-chloro-2-fluorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 601513-18-2 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-(2-bromo-4-chlorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 601513-19-3 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-(4-chloro-2-iodophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 601513-35-3 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-[4-chloro-2-(trifluoromethyl)phenyl]-7-methoxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 601513-44-4 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-(2,4-dichlorophenyl)-7-methoxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]-(9CI) (CA INDEX NAME)




RN 618885-77-1 HCAPLUS

CN 2H-1-Benzopyran-2-one, 7-(acetyloxy)-3-(4-chlorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]-(9CI) (CA INDEX NAME)



RN 618885-78-2 HCAPLUS

CN 2H-1-Benzopyran-2-one, 7-(acetyloxy)-3-(2,4-dichlorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 618885-79-3 HCAPLUS

CN 2H-1-Benzopyran-2-one, 7-(acetyloxy)-3-(4-chloro-2-fluorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


10/21/2005

10685722.trn




RN 618885-80-6 HCAPLUS

CN 2H-1-Benzopyran-2-one, 7-(acetyloxy)-3-(2-bromo-4-chlorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 618885-81-7 HCAPLUS

CN 2H-1-Benzopyran-2-one, 7-(acetyloxy)-3-(4-chloro-2-iodophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 618885-82-8 HCAPLUS

CN 2H-1-Benzopyran-2-one, 7-(acetyloxy)-3-[4-chloro-2-(trifluoromethyl)phenyl]-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]-(9CI) (CA INDEX NAME)



REFERENCE COUNT:

1


THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2005 ACS on STN

10/21/2005 10685722.trn

ACCESSION NUMBER: 2003:730534 HCAPLUS  
DOCUMENT NUMBER: 139:261167  
TITLE: Preparation of benzopyranones for inhibiting  
interleukin-6  
INVENTOR(S): Mckie, Jeffrey A.; Bhagwat, Shripad S.; Renaud,  
Johanne; Missbach, Martin  
PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA  
SOURCE: U.S., 21 pp.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
<del>US 6620838</del>	B1	20030916	US 2002-125965	20020419
US 2004092572	A1	20040513	US 2003-412997	20030414
CA 2482986	AA	20031030	CA 2003-2482986	20030418
WO 2003089422	A1	20031030	WO 2003-US12283	20030418
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1497277	A1	20050119	EP 2003-733871	20030418
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPLN. INFO.:			US 2002-125965	A2 20020419
			US 2003-412997	A 20030414
			WO 2003-US12283	W 20030418
OTHER SOURCE(S):	MARPAT 139:261167			
GI				



AB The title benzopyranones [I; n = 2-4; R1 = H, COR2, CO2R2, etc.; R2 = alkyl, aryl, arylalkyl, etc.; X = H, halo, CF3; Y = halo, CF3], useful for treating a bone-resorbing disease, cancer, arthritis or an estrogen-related condition such as breast cancer, osteoporosis and endometriosis, were prepared E.g., a 4-step synthesis of I [n = 2; R1 = H;

X = Cl; Y = CF<sub>3</sub>] (starting from tert-Bu acetate and 3-chloro-4-iodobenzotrifluoride) which showed IC<sub>50</sub> of 0.4 nM against IL-6, was given. The compds. I, wherein R<sub>1</sub> = H, can be prepared by demethylation of the corresponding phenolic Me ether. Pharmaceutical composition comprising the compound I was claimed.


IT 601513-02-4P 601513-05-7P 601513-06-8P  
601513-07-9P 601513-17-1P 601513-18-2P  
601513-19-3P 601513-20-6P 601513-21-7P  
601513-22-8P 601513-23-9P 601513-24-0P  
601513-25-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzopyranones for inhibiting interleukin-6)


RN 601513-02-4 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-[4-chloro-2-(trifluoromethyl)phenyl]-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 601513-05-7 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-(4-chlorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]-, hydrochloride (9CI) (CA INDEX NAME)




RN 601513-06-8 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-(2,4-dichlorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 601513-07-9 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-(4-chlorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 601513-17-1 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-(4-chloro-2-fluorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 601513-18-2 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-(2-bromo-4-chlorophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 601513-19-3 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-(4-chloro-2-iodophenyl)-7-hydroxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 601513-20-6 HCAPLUS

CN 2H-1-Benzopyran-2-one, 7-acetyl-3-(4-chlorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 601513-21-7 HCAPLUS

CN 2H-1-Benzopyran-2-one, 7-acetyl-3-(2,4-dichlorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 601513-22-8 HCAPLUS

CN 2H-1-Benzopyran-2-one, 7-acetyl-3-(4-chloro-2-fluorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 601513-23-9 HCAPLUS

CN 2H-1-Benzopyran-2-one, 7-acetyl-3-(2-bromo-4-chlorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 601513-24-0 HCAPLUS

CN 2H-1-Benzopyran-2-one, 7-acetyl-3-(4-chloro-2-iodophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-25-1 HCAPLUS

CN 2H-1-Benzopyran-2-one, 7-acetyl-3-[4-chloro-2-(trifluoromethyl)phenyl]-4-  
[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




IT 601513-35-3P 601513-44-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of benzopyranones for inhibiting interleukin-6)

RN 601513-35-3 HCAPLUS


CN 2H-1-Benzopyran-2-one, 3-[4-chloro-2-(trifluoromethyl)phenyl]-7-methoxy-4-

[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 601513-44-4 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-(2,4-dichlorophenyl)-7-methoxy-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

87


THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=&gt; d 18 ibib abs hitstr tot

L8 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN  
 ACCESSION NUMBER: 2004:354751 HCAPLUS  
 DOCUMENT NUMBER: 140:350547  
 TITLE: Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer  
 INVENTOR(S): Friedman, Glenn; McKie, Jeffrey; Wright, Jonathan  
 PATENT ASSIGNEE(S): Signal Pharmaceuticals, Llc, USA  
 SOURCE: PCT Int. Appl., 34 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004035002	A2	20040429	WO 2003-US32932	20031015
WO 2004035002	A3	20040826		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004225005	A1	20041111	US 2003-685722	20031014
CA 2502064	AA	20040429	CA 2003-2502064	20031015
EP 1556374	A2	20050727	EP 2003-777639	20031015
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003015400	A	20050816	BR 2003-15400	20031015
PRIORITY APPLN. INFO.:			US 2002-418469P	P 20021015
			US 2003-685722	A 20031014
			WO 2003-US32932	W 20031015

OTHER SOURCE(S): MARPAT 140:350547  
 GI



AB This invention relates to benzopyranone compds., compns. comprising a benzopyranone compound and methods for treating or preventing cancer or inhibiting the growth of a cancer cell or neoplastic cell comprising

administering an effective amount of a benzopyranone compound. The benzopyranone compds. have the formula I, or a pharmaceutically acceptable salt thereof, wherein R1 is halogen, trifluoromethyl or C1-6 alkyl. A solution of the phenolbenzopyranone (0.74 mmol), triphenylphosphine (1.1 mmol), and 1-(2-hydroxyethyl)pyrrolidine (1.1 mmol) in THF/CH<sub>2</sub>Cl<sub>2</sub> (8 mL) was treated with DIAD (1.1 mmol) and the reaction mixture was stirred at room temperature for about 6 h. The reaction mixture was concentrated and the crude

product was purified using flash chromatog. to provide about 35 mg (10%) of 13-(4-chlorophenyl)-7-fluoro-4-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-chromen-2-one.


IT 681813-32-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(benzopyranone compds., compns. thereof, and methods for treating or preventing cancer)

RN 681813-32-1 HCAPLUS

CN 2H-1-Benzopyran-2-one, 3-(4-chlorophenyl)-7-fluoro-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L8 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:730534 HCAPLUS

DOCUMENT NUMBER: 139:261167

TITLE: Preparation of benzopyranones for inhibiting interleukin-6

INVENTOR(S): Mckie, Jeffrey A.; Bhagwat, Shripad S.; Renaud, Johanne; Missbach, Martin

PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA

SOURCE: U.S., 21 pp.

CODEN: USXXAM


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6620838	B1	20030916	US 2002-125965	20020419
US 2004092572	A1	20040513	US 2003-412997	20030414
CA 2482986	AA	20031030	CA 2003-2482986	20030418
WO 2003089422	A1	20031030	WO 2003-US12283	20030418
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1497277	A1	20050119	EP 2003-733871	20030418
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2002-125965	A2 20020419
			US 2003-412997	A 20030414
			WO 2003-US12283	W 20030418

OTHER SOURCE(S): MARPAT 139:261167  
GI



AB The title benzopyranones [I; n = 2-4; R1 = H, COR2, CO2R2, etc.; R2 = alkyl, aryl, arylalkyl, etc.; X = H, halo, CF3; Y = halo, CF3], useful for treating a bone-resorbing disease, cancer, arthritis or an estrogen-related condition such as breast cancer, osteoporosis and endometriosis, were prepared E.g., a 4-step synthesis of I [n = 2; R1 = H; X = Cl; Y = CF3] (starting from tert-Bu acetate and 3-chloro-4-iodobenzotrifluoride) which showed IC50 of 0.4 nM against IL-6, was given. The compds. I, wherein R1 = H, can be prepared by demethylation of the corresponding phenolic Me ether. Pharmaceutical composition comprising the compound I was claimed.

IT 601513-20-6P 601513-21-7P 601513-22-8P  
601513-23-9P 601513-24-0P 601513-25-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzopyranones for inhibiting interleukin-6)

10/21/2005 10685722.trn


RN 601513-20-6 HCAPLUS

CN 2H-1-Benzopyran-2-one, 7-acetyl-3-(4-chlorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl] - (9CI) (CA INDEX NAME)



RN 601513-21-7 HCAPLUS


CN 2H-1-Benzopyran-2-one, 7-acetyl-3-(2,4-dichlorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl] - (9CI) (CA INDEX NAME)



RN 601513-22-8 HCAPLUS


10/21/2005 10685722.trn

CN 2H-1-Benzopyran-2-one, 7-acetyl-3-(4-chloro-2-fluorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl] - (9CI) (CA INDEX NAME)



RN 601513-23-9 HCAPLUS


CN 2H-1-Benzopyran-2-one, 7-acetyl-3-(2-bromo-4-chlorophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl] - (9CI) (CA INDEX NAME)



RN 601513-24-0 HCAPLUS


CN 2H-1-Benzopyran-2-one, 7-acetyl-3-(4-chloro-2-iodophenyl)-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl] - (9CI) (CA INDEX NAME)

pyrrolidinyl)ethoxy]phenyl]methyl] - (9CI) (CA INDEX NAME)



RN 601513-25-1 HCAPLUS

CN 2H-1-Benzopyran-2-one, 7-acetyl-3-[4-chloro-2-(trifluoromethyl)phenyl]-4-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]methyl] - (9CI) (CA INDEX NAME)



REFERENCE COUNT:

87

THERE ARE 87 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/21/2005 10685722.trn

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

44.38

368.11

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-5.11

-5.11

STN INTERNATIONAL LOGOFF AT 12:49:07 ON 21 OCT 2005